This may very well be the largest week for biotech IPOs in years — even when the federal government stays shuttered briefly.
Authorities funding lapsed this previous Saturday, sparking a partial authorities shutdown that has closed companies not deemed important for public security and nationwide safety. The record of closed companies consists of the Securities and Change Fee, which should log out on an IPO submitting earlier than an organization can go public.
The shutdown may very well be temporary. Home Speaker Mike Johnson stated on Meet the Press that he expects the Senate-passed funding invoice will go to a vote within the Home of Representatives by Tuesday. However till the federal government reopens, the SEC’s operations plan states the company is not going to course of new or pending registration statements.
Throughout all sectors, as many as eight firms are lined up for IPOs this week, in keeping with IPO analysis agency Renaissance Capital. If all eight value their choices this week, it will mark probably the most lively week for IPOs since 2021, Renaissance stated. 4 on this record are biotech firms: Eikon Therapeutics, Veradermics, AgomAb Therapeutics, Spyglass Pharma. These biotechs may nonetheless go public even with the SEC closed. Earlier than the federal government shut down, the company late Friday filed a discover of effectiveness for each. The submitting is an SEC declaration {that a} registration assertion has met all the company’s authorized and regulatory necessities, clearing the corporate to proceed with an IPO.
Although 2025 IPO exercise didn’t attain the heights many had hoped, the overall variety of new public firms nonetheless marked a four-year excessive, in keeping with Renaissance’s 2026 IPO outlook report. The agency counted 202 firms that went public in 2025, elevating $44 billion. These figures proceed the upward development in IPOs since a drop-off after the 2021 peak, when 397 IPOs raised $142.4 billion, in keeping with the report.
Stabilizing macroeconomic situations after tariff volatility in 2025 together with cooling inflation and declining rates of interest are among the many components that Renaissance sees driving IPO exercise this yr. The agency additionally stated there’s a sturdy backlog of firms ready to go public, lots of them near-term IPO candidates. Renaissance tasks 200 to 230 IPOs throughout all sectors this yr will elevate between $40 billion and $60 billion.
Wealthy Segal, a accomplice at Cooley, stated the strong IPO markets of 2020 and 2021 was not regular, and he doesn’t suppose the expectation ought to be that exercise will return to these ranges. Cooley sees a progressive improve in IPOs for 2026. Segal added that there’s typically IPO exercise across the J.P. Morgan Healthcare Convention every January. Aktis Oncology had the primary biotech IPO of 2026debuting on the Nasdaq simply forward of the convention.
Eikon, Veradermics, SpyGlass, and AgomAb all timed the filings of their registration statements to coincide with the JPM convention. Final week, these firms up to date their filings with preliminary monetary phrases for his or her deliberate IPOs. Segal stated that when the brand new yr begins, many buyers wish to see the rapid prior yr financials. Some firms might push out an IPO date additional to allow them to present these knowledge.
There’s one other strategy to go public throughout a authorities shutdown. Beneath Part 8(a) of the Securities Act, a registration assertion turns into efficient 20 days after it’s filed. Shashi Khiani, shareholder within the securities and company finance apply at Polsinelli, notes that almost all firms don’t wish to go public this fashion in order that they embody an modification to the submitting that delays effectiveness till the corporate is notified by the SEC. That’s as a result of if an organization begins promoting shares and the SEC later finds an issue with the prospectus, the corporate may face enforcement motion from the regulator and lawsuits from shareholders. Corporations that pursue this path to the general public markets are seemingly additional alongside within the SEC evaluate of the prospectus, Khiani stated.
“Corporations who’ve been by a few rounds with the SEC now, the place they’ve a modicum of consolation that they’ve addressed the SEC’s feedback and there’s no situation, I feel they is perhaps stronger candidates or extra seemingly to make use of this feature,” he defined.
Due to the authorized dangers, Khiani has been advising shoppers to not go public utilizing the Part 8(a) rule. However two biotechs did use this rule to go public throughout the 43-day authorities shutdown final fall: MapLight Therapeutics and Evommune. Cooley suggested each biotechs on their IPOs, although Segal was not concerned in both one. Talking typically, Segal stated utilizing Part 8(a) to go public just isn’t one thing an organization would do when the federal government is open.
“It’s positively a tactic of final resort,” he stated. “I don’t suppose anyone’s doing it as the primary choice, but when the federal government continues to close down, we are going to seemingly proceed to see different firms do that. However I feel it’s going to be small numbers. If the federal government’s open and functioning, folks will do it the common means.”
At the least one biotech firm has joined the general public markets throughout the present authorities shutdown. Polaryx Therapeutics went public Monday through a direct itemizing, during which firm insiders promote their shares on to the general public with out involving underwriters. Going public this fashion nonetheless requires the SEC to log out on the registration assertion. The SEC gave the inexperienced gentle to the Polaryx submitting and issued a discover of effectiveness final week, earlier than the shutdown.
Not like a standard IPO, a direct itemizing doesn’t elevate new cash for a corporation. Meaning Polaryx nonetheless wants to search out capital for its scientific trial plans. Lead Polaryx drug candidate PLX-200 is on observe to enter a Section 2 examine within the first half of this yr testing the drug in uncommon lysosomal storage problems. In keeping with Polaryx’s prospectusthe corporate’s money place was $5.7 million on the finish of the third quarter of 2025. The submitting doesn’t provide estimates for the scientific trial prices, however states that Polyaryx expects its capital will final solely by the third quarter of this yr.
Photograph: Angela Weiss/AFP, through Getty Photographs
